
Opinion|Videos|November 15, 2024
Importance of Early Referral for CAR T-cell Therapy in Multiple Myeloma and Patient Quality of Life
Panelists discuss how early referral for chimeric antigen receptor T-cell therapy is crucial for patients, as it helps to overcome potential barriers and ensures timely access to this transformative treatment option.
Advertisement
Episodes in this series

Dr Ajai Chari to Dr Martin: As we know, thereare potential barriers or challenges in referring patients to chimeric antigen receptor (CAR) T-cell therapy; why is it important for patients to be referred early for CAR T-cell therapy?
Advertisement
Related to this article

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The Pan-Mass Challenge donated a record $80 million to Dana-Farber Cancer Institute to support cancer research, treatment, and patient care.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
FDA Issues CRL to Ivonescimab Plus Chemo for Locally Advanced or Metastatic NSCLC
5

